Download Free An Update On Sars Cov 2 Book in PDF and EPUB Free Download. You can read online An Update On Sars Cov 2 and write the review.

The emergence of severe acute respiratory syndrome (SARS) in late 2002 and 2003 challenged the global public health community to confront a novel epidemic that spread rapidly from its origins in southern China until it had reached more than 25 other countries within a matter of months. In addition to the number of patients infected with the SARS virus, the disease had profound economic and political repercussions in many of the affected regions. Recent reports of isolated new SARS cases and a fear that the disease could reemerge and spread have put public health officials on high alert for any indications of possible new outbreaks. This report examines the response to SARS by public health systems in individual countries, the biology of the SARS coronavirus and related coronaviruses in animals, the economic and political fallout of the SARS epidemic, quarantine law and other public health measures that apply to combating infectious diseases, and the role of international organizations and scientific cooperation in halting the spread of SARS. The report provides an illuminating survey of findings from the epidemic, along with an assessment of what might be needed in order to contain any future outbreaks of SARS or other emerging infections.
Coronavirus Drug Discovery, Volume 1: SARS-CoV-2 (COVID-19) Prevention, Diagnosis, and Treatment is the first of three volumes presenting comprehensive information on drug discovery against COVID-19. This volume provides background information on the genesis of COVID-19, the epidemiology, transmission, pathogenesis, and mutagenesis. It also presents the various treatment options, drug discovery opportunities and vaccine developmental processes. Written by global team of experts from key institutions across the globe, this book is recommended to all concerned agencies, private research firms, and consortiums working on finding a solution to COVID-19 and its variants. By design, this book will be useful to drug developers, medicinal chemists, pharmacologists, health experts, researchers, students and faculty members in industry and academia. - Presents information on the genesis of COVID-19, global impact and collaborative efforts - Details the epidemiology, transmission, pathogenesis, and mutagenesis of SARS-CoV-2 - Documents the various treatment options and vaccine development for COVID-19
From former New York Times reporter Alex Berenson, the second installment in the best-selling series that offers hard data about the coronavirus epidemic - rather than hysterical predictions of doom.While Unreported Truths Part 1 focused on how many people are dying from COVID-19, this section discusses an equally important but even more complex topic: the history of lockdowns, and the evidence that they work as intended. Like Part 1, this section draws on primary sources like Centers for Disease Control and World Health Organization reports, along with news articles, government documents, and scientific papers.In three chapters, this section explains the surprising scientific debate around lockdowns BEFORE March, along with the evidence that they did or did not work as intended to reduce the spread of the coronavirus and save lives. If you have been wondering whether lockdowns made any difference - as the media has loudly insisted - Part 2 will give you the truthful, accurate and well-sourced information you need to make up your own mind.Please note: This booklet contains only the second section of Unreported Truths. Part 1 is available separately.
This update on SARS-CoV-2 focuses on basic knowledge about the virus and COVID-19 treatment. Chapters present basic information about the disease and its treatment. The virology, epidemiology, etiology, and damage response framework of SARS-CoV-2 are also discussed in detail. The book also covers recent topics of interest to pharmacology scholars such as the immunopathogenesis of SARS-CoV2, nanotechnology, repurposed drug treatments, COVID-19 vaccines, and phytomedicine for COVID-19 therapeutics. Readers in pharmacology, virology and medicine will find the book a simple, yet informative update on SARS-CoV-2 and COVID-19 treatment.
As the dawn of 2020 arrived, a new threat to Mankind was revealed in the form of- novel Corona Virus, claiming lives incessantly all over the world. Starting in the end of 2019, December, this strain of Corona virus was first isolated from Wuhan, China. The never before identified strain of Corona virus in man, was named as novel Corona virus (2019-nCoV). The infection caused has now been named as Coronavirus Disease 2019 (COVID19). With the physicians still to learn about its behaviour and with no cure at hand, the disease turned into pandemic very soon. World Health Organization instructed all information regarding COVID-19 accessible, so as to doctors and health workers all over the world can use it for better management of the patients globally. Association of Physicians of India has also followed the foot-steps of WHO and has committed itself for the integration of knowledge among the nation and its members regarding COVID-19 through this book Clinical Updates on COVID- 19. As severe forms of the infection have been encountered by the individuals suffering from co-morbidities, this book has addressed Covid 19 infection in such patients with great details. Hope this book will be helpful for all the practicing physicians and resident doctors in combating this Pandemic all over the world.
In May 2023, WHO declared that COVID-19 was no longer a public health emergency of international concern. In 2024, COVID-19 certainly has not gone away, but we can now take a more reflective look at the pandemic. This issue of the ERS Monograph does just that, bringing together a truly international group of experts, as befits a global illness, to consider areas such as: long-term sequelae in airway disease, interstitial lung disease, and in the immunocompromised; therapeutics in the community, in hospital and in the intensive care unit; and the pathophysiology and management of long COVID. The Guest Editors also consider the impact of COVID-19 on clinical research and scientific publishing, as well as looking to the future, considering what can be learnt from the pandemic.
Coronavirus disease 2019 (COVID-19), produces the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with atypical pneumonia. This infection is a global health challenge producing post-acute sequelae of SARS-CoV-2 infection (PASC), including neuro-PASC in which direct or indirect invasion of the virus into the brain causes immune dysregulation, hormonal disorders, elevated cytokine levels due to immune reaction and chronic inflammation, direct tissue injury, and persistent low-grade infection. The COVID-19 induced-neuroinflammation promotes blood-brain barrier (BBB) disruption, access of antigens and inflammatory factors into the brain, as well as infection or immune-mediated response in the neuromuscular system. It is therefore necessary to explore whether there is a close correlation with the adenosine pathway, the activation of the ACE receptor by the virus, the concentration of IL6 and the neuro-invasive effect of COVID-19. Other points of interest are the analysis of the autonomic dysfunction induced by cytokines; the effect of vaccine mRNA delivery in Central and Peripheral Nervous System, the long-term effects of Covid 19 infection and/or therapeutic approach in different pandemic countries. In this Research Topic we aim to including submissions and research from different countries, which will allow comparisons of loco-regional clinical experiences, diagnostic flow-charts, and different therapeutic approaches.
SARS-CoV-2, the coronavirus responsible for COVID-19, wreaked havoc on the world; it could both spread easily and mutate rapidly, leading to the decrease in the effectiveness of newly developed vaccines over time. The detection of these mutated variants and the development of more efficient vaccines requires significant effort and increased knowledge in this field. This new book, SARS-CoV-2 Variants and Global Population Vulnerability: Diagnostic Strategies, Vaccine Development, and Therapeutic Management, provides detailed and systemic information regarding the biology and immunophysiology of SARS-CoV-2 and highlights the global vulnerability of the world population to SARS-CoV-2 infection and COVID-19. The book covers different aspects pertaining to the SARS-CoV-2 variants and their relation to global vulnerability. Chapters discuss the diagnostics, vaccine development, and therapeutic management starting from the zoonotic origin, organization, and transmission of SARS-CoV-2, lifestyle and immunophysiology of the virus, detection and diagnosis techniques, and analytical techniques. The book also observes the global impact of Delta and Omicron SARS-CoV-2 variants. It looks at the drug repurposing and new drug discovery routines for the emerging variants. It presents strategies for fast-track vaccine development, the roles of nasal vaccines and nucleic acid vaccines for COVID-19 management, monoclonal antibody therapy for the diseases management, along with the use of dietary supplements and nutraceuticals, herbal drugs, and other alternative remedies for COVID-19 management. The book also considers the social and environmental impacts of SARS-CoV-2 variants and the current challenges, outlining aspects that can help in developing more efficacious means for controlling SARS-CoV-2 in the future. Key highlights: Discusses SARS-CoV-2 variants, diagnosis strategies, vaccine development, and the therapeutic management of the disease Provides comprehensive coverage of SARS-CoV-2 virus and variants With its unique and thorough take on the subject, this book is an important resource of know-how for investigators working in this area. Professionals from the pharmaceutical industry as well as students, research scholars, doctors, and other healthcare professionals will find this book of particular value.
The SARS-CoV-2 virus has led to the worldwide outbreak of the twentieth century. Current knowledge on SARS-CoV-2 acute infection has dramatically increased. Three years after the main outbreak, the presence of long-lasting symptoms after the acute infection called long COVID or post-COVID-19 syndrome, affects millions of individuals worldwide. Increasing literature supports the presence of more than 100 potential symptoms after the acute phase of infection such as: · extreme fatigue, dizziness, and insomnia · depression and anxiety, memory and concentration impairments · loss of smell or taste, tinnitus, and earaches · chest pain, heart palpitations, tightness, muscle aches. However, several gaps still are present in the identification, timeframe, mechanisms, and treatment strategies for the management of long-COVID.
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has probably been the most important disease to emerge in the 21st century. This viral zoonotic disease has been a significant cause of morbidity and mortality worldwide, but with a higher impact in low- and middle-income countries of Africa, Asia, and Latin America. Up to December 4, 2022, more than 645,195,564 cases had been reported globally, with 6,640,845 deaths, and more than 13,054,668,703 doses of a vaccine had been given. Research has been of the utmost importance in the COVID-19 crisis: a great deal of knowledge was gathered between December 2019 and December 2022. Appropriate evidence-based management and the development of safe and effective vaccines have been key to controlling the virus. This book presents a selection of the last two years’ learning from research and clinical practice concerning SARS-CoV-2/COVID-19.